Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...

Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving intensive care units ...

Observational study data suggest that SGLT2 inhibitor use reduces risks for kidney and cardiovascular events even in patients with an eGFR less than 15 mL/min/1.73 m2 who have type 2 diabetes.

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may improve CV outcomes in patients with diabetes undergoing cancer therapy. The ...

Sotagliflozin (Inpefa; Lexicon Pharmaceuticals), a dual sodium-glucose co-transporter 1/2 inhibitor, appears to reduce both MACE and stroke risk among patients with type 2 diabetes, chronic kidney ...

The most important feature in all of these initial cases is that the patients did not recognize they had ketoacidosis, which is typically associated with severe hyperglycemia. As a result, instead of ...